RxDoctor Payments Data

Anita Kaw, MD

Internal Medicine · Middletown, NYNPI 1639365463

Payments from drug & device makers

$4,051in general payments, 2019–2025

Across 195 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$839
  • AstraZeneca$668
  • AbbVie$581
  • GSK$479
  • Novo Nordisk$311
  • Exact Sciences$197
  • plus $976 from 14 others

What the payments were for

  • Food & beverage$4,051100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,051 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$172,925
Medicare patients
275
Services billed
6,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$92,313
MounjaroTirzepatide68$80,966
EliquisApixaban50$65,417
JardianceEmpagliflozin31$37,657
FarxigaDapagliflozin Propanediol27$37,391
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$23,682
TrulicityDulaglutide17$18,631
TradjentaLinagliptin16$13,576
Breo ElliptaFluticasone/Vilanterol13$9,391
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$7,148
Spiriva RespimatTiotropium Bromide12$6,986
Albuterol Sulfate HfaAlbuterol Sulfate74$2,573
Atorvastatin Calcium256$2,492
Rosuvastatin Calcium108$2,230
Levothyroxine Sodium136$1,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$839$99,59785 claims
Novo NordiskOzempic$311$92,31368 claims
PfizerEliquis$167$65,41750 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$135$58,21959 claims
AstraZenecaFarxiga$668$37,39127 claims
GSKTrelegy Ellipta, Breo Ellipta$479$33,07351 claims
AbbVieSynthroid$581$1,56818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →